此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Nebulized Plus Intravenous Versus Intravenous Furosemide in Pulmonary Edema

2026年11月12日 更新者:Muhammad Tausif Khan、Federal Government Polyclinic - Post Graduate Medical Institute (FGPC-PGMI)

Effectiveness of Nebulized Plus Intravenous Furosemide Versus Intravenous Furosemide in Treating Pulmonary Edema: A Randomized Controlled Trial

This randomized controlled trial compares intravenous furosemide alone with intravenous plus nebulized furosemide in adults with acute pulmonary edema. The main outcome is the change in peripheral oxygen saturation (SpO2) from baseline, and the secondary outcome is the change in dyspnea severity on a 0-10 visual analogue scale. The trial will test whether adding nebulized furosemide to standard intravenous furosemide gives additional benefit.

研究概览

详细说明

Pulmonary edema is a medical emergency in which fluid collects in the alveolar spaces, impairing gas exchange and causing respiratory distress. Intravenous furosemide is the mainstay of treatment but may cause hypotension, electrolyte imbalance and renal dysfunction. Nebulized furosemide delivers the drug directly to the lungs and may improve dyspnea and oxygenation through local effects. Most available studies have tested nebulized furosemide as an alternative to intravenous therapy rather than as an adjunct, so it remains unclear whether the combination offers added benefit over intravenous furosemide alone.

Methods: A randomized controlled trial will be conducted in the Department of Medicine, Federal Government Polyclinic Hospital, Islamabad, over 6 months after ethical approval, using non-probability consecutive sampling. A total of 130 patients (65 per group) will be enrolled. Sample size was calculated with the WHO formula for two means (alpha 0.05, power 80%, SD 1.5, expected difference 0.7) based on Barzegari et al. (2021). After written informed consent, baseline demographics, vital signs, SpO2 and dyspnea VAS score will be recorded. All patients will receive standard initial care with oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg. Patients will be randomized 1:1 using a computer-generated sequence with sequentially numbered, opaque, sealed envelopes. Group A will receive intravenous furosemide 1 mg/kg plus nebulized furosemide 40 mg in 4 ml 0.9% saline, and Group B will receive intravenous furosemide 1 mg/kg alone. SpO2 and dyspnea VAS will be recorded at baseline and at 30, 60 and 120 minutes after intervention.

Statistical analysis: Data will be analyzed in SPSS version 23. Continuous variables will be presented as mean and standard deviation. Between-group comparison of change from baseline in SpO2 and VAS will be done with the independent samples t-test, or the Mann-Whitney U test for non-normal data. Baseline SpO2, baseline dyspnea score, oxygen flow rate, use of nitrates or morphine and underlying cardiac function will be recorded as potential confounders. A p-value below 0.05 will be considered significant.

研究类型

介入性

注册 (估计的)

130

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Islamabad
      • Islamabad、Islamabad、巴基斯坦、44000
        • Department of Medicine, Federal Government Polyclinic Hospital
        • 首席研究员:
          • Tausif Khan

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 94年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adults aged 18 to 94 years
  • Acute shortness of breath within the past 6 hours
  • Clinical features of pulmonary edema (tachypnea, use of accessory muscles, crepitations, wheeze, gallop rhythm) with chest X-ray showing bilateral pulmonary infiltrates consistent with pulmonary edema, with or without cardiomegaly, pulmonary vascular congestion, Kerley B lines or pleural effusion

Exclusion Criteria:

  • Cardiogenic shock or systolic blood pressure below 90 mm Hg
  • Need for intubation, cardiac arrhythmia or liver failure
  • COPD or asthma exacerbation
  • End-stage renal disease on dialysis
  • Allergy to furosemide

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Group A: IV plus nebulized furosemide

Intravenous furosemide 1 mg/kg slow push over 5 minutes plus nebulized furosemide 40 mg diluted in 4 ml 0.9% saline over 15 minutes, in addition to standard initial care (oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg).

Furosemide 40 mg diluted in 4 ml 0.9% saline given by jet nebulizer over 15 minutes.

其他名称:
  • 乳胶

Furosemide 1 mg/kg given as a slow intravenous push over 5 minutes.

其他名称:
  • 乳胶
有源比较器:Group B: IV furosemide

Intravenous furosemide 1 mg/kg slow push over 5 minutes, in addition to standard initial care (oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg).

Furosemide 1 mg/kg given as a slow intravenous push over 5 minutes.

其他名称:
  • 乳胶

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in peripheral oxygen saturation (SpO2)
大体时间:Baseline, 30, 60 and 120 minutes after intervention (primary comparison at 60 minutes)

SpO2 (%) measured with a calibrated pulse oximeter; change from baseline will be compared between groups.

Baseline, 30, 60 and 120 minutes after intervention (primary comparison at 60 minutes)

次要结果测量

结果测量
措施说明
大体时间
Change in dyspnea severity on Visual Analogue Scale (VAS)
大体时间:Baseline, 30, 60 and 120 minutes after intervention

Patient-rated breathlessness on a 0-10 VAS (0 = no breathlessness, 10 = worst breathlessness); change from baseline will be compared between groups.

Baseline, 30, 60 and 120 minutes after intervention

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Tausif Khan, MBBS, FCPS Trainee、Federal Government Polyclinic Hospital, Islamabad

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2027年5月1日

研究完成 (估计的)

2027年6月1日

研究注册日期

首次提交

2026年11月12日

首先提交符合 QC 标准的

2026年11月12日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅